Sequencing was completed on Ion GeneStudio S5 and analyzed with the software provided by the manufacturer (Thermo Fisher Scientific, Waltham, USA). by cross-reacting antibodies in many variants. The assay facilitated the one-step recognition of immunogenic regions of proteins that efficiently induced specific IgG in SARS-CoV-2-infected individuals. We recognized four areas demonstrating both significant immunogenicity and the activity of a cross-reacting IgG hotspot in protein S (located at NTD, RBD, HR1, and HR2/TM domains) and two such areas in protein N (at 197280 and 358419 aa positions). This novel method for identifying cross-reacting IgG hotspots keeps promise for informing vaccine design and serological diagnostics for COVID-19 and additional infectious diseases. Keywords:SARS-CoV-2, COVID-19, antibodies, IgG, epitopes, phage display, serological profiling == 1. Intro == UNC-1999 Efficient immunological safety in COVID-19 is currently the major element shaping the global perspective within the growth or downturn of further pandemic waves. The SARS-CoV-2 disease offers constantly been producing a multitude of variants; many of these variants, such as Delta or Omicron, induced pandemic waves obviously using evasion of existing immunity against the disease to spread within the global human population [1,2]. Importantly, antigenic drift, driven from the pressure from specific immunity exerted within the disease, significantly contributes to the selection of new variants able to evade immunological control [3]. For UNC-1999 these reasons, Rabbit polyclonal to KLK7 the hope for efficient control and suppression of the pandemic just through global vaccinations and immunological memory space from previous infections has been tempered. Virus-specific antibodies are, in fact, a pool of antibodies focusing on different structural proteins. Structural proteins of SARS-CoV-2 include nucleocapsid protein (protein N), spike protein (protein S), envelope protein (protein E), and membrane protein (protein M) [4]. The most important target for the immune response is protein S, due to the virus-blocking potential of antibodies focusing on this protein. This protein mediates binding to the ACE2 receptor; therefore, antibodies focusing on the S protein may neutralize the disease. The S protein is definitely relatively large, 1273 amino acids (aa) long (acc. no.:YP_009724390.1), and it consists of two major domains: S1 and S2. The S1 subunit function is definitely binding to receptors in human being cells. Its major parts are the N-terminal website (NTD) and receptor binding website (RBD). The S2 subunit, in turn, is definitely engaged in the viral and sponsor cell membranes fusion. S2 consists of the cytoplasmic tail (CT), transmembrane website (TM), heptad repeat 1 (HR1), heptad repeat 2 (HR2), fusion peptide (FP), central helix (CH), and connector website (CD). Also, the cleavage site S1/S2 takes on a key part in disease access to a human being sponsor cell. Linear epitopes within the S protein have been demonstrated to elicit neutralizing antibodies in COVID-19 individuals [5]. The N protein, in turn, can be a target for serological diagnostics, and at the beginning of pandemics, it was used in the majority of serological tests. Later on, it was replaced by protein S, due to the direct indicator of S-targeting reactions within the neutralization potential of antibodies, and also due to potential problems with specific response induction in asymptomatic infections. However, the relatively conserved protein N is still becoming used to confirm SARS-CoV-2-related etiology of already cleared infections, since the N protein is unique for SARS-CoV-2, highly immunogenic, and not included in anti-COVID-19 vaccines [6]. Two additional proteins, M and E, seem to have lower significance as potential focuses on for specific antibodies. However, one cannot exclude the part of these antibodies in disease inhibition. After two years of the pandemic and the continuous emergence of fresh variants, it is demanding to thoroughly understand all the possible mixtures of earlier UNC-1999 infections, numerous vaccination types, and potential exposure to new variants in an individual patient. These mixtures further generate myriads of options at the population level. Thus, instead of variant-to-variant comparisons, the recognition of.